Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
804 days ago
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
1059 days ago
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1086 days ago
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1158 days ago
China Data On Tap For Friday
China will on Friday release a batch of data on Friday, headlining a busy day for Asia-Pacific economic activity. On tap are October figures for fixed asset investment, industrial production, retail sales, house prices and unemployment.
RTTNews
|
1h 3min ago
New Zealand Manufacturing Sector Moves To Expansion - BusinessNZ
The manufacturing sector moved back up into expansion territory in October, the latest survey from Business New Zealand revealed on Friday with a Performance of Manufacturing Index score of 51.4.
RTTNews
|
1h 20min ago
TSX Tumbles 2%; Technology, Financials Stocks Down Sharply
The Canadian market is down sharply Thursday afternoon, weighed down by a sell-off in tech stocks amid concerns about high valuations. Shares from healthcare, utilities and financials sectors are the other major losers.
RTTNews
|
4h 21min ago
Swiss Market Ends Weak
The Switzerland market ended on a weak note on Thursday as stocks failed to hold early gains and drifted lower with investors taking some profits, cashing in recent gains.
RTTNews
|
4h 57min ago
